Skip to main content
letter
. 2021 Nov 17;11(1):1–7. doi: 10.1007/s40119-021-00245-3
Hospitalized COVID-19 patients with acute myocardial injury have more than fourfold higher mortality than those without such injury.
Familial hypercholesterolemia (FH), a common genetic disease, affects over 30 million individuals worldwide, and if left untreated leads to premature atherosclerotic cardiovascular disease.
Recent population-based analysis showed that FH patients with COVID-19 are at a significantly elevated risk of acute myocardial injury.
Preventive lipid management among FH patients suffering from COVID-19 needs to be continued, or even intensified, during the infection and beyond.